275 related articles for article (PubMed ID: 22973953)
1. Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer.
Galvani E; Alfieri R; Giovannetti E; Cavazzoni A; La Monica S; Galetti M; Fumarola C; Bonelli M; Mor M; Tiseo M; Peters GJ; Petronini PG; Ardizzoni A
Curr Pharm Des; 2013; 19(5):818-32. PubMed ID: 22973953
[TBL] [Abstract][Full Text] [Related]
2. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
Ou SH; Soo RA
Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
[TBL] [Abstract][Full Text] [Related]
3. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
Zhang K; Yuan Q
J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
[TBL] [Abstract][Full Text] [Related]
4. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
Tan CS; Cho BC; Soo RA
Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
[TBL] [Abstract][Full Text] [Related]
5. Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance.
Jotte RM; Spigel DR
Cancer Med; 2015 Nov; 4(11):1621-32. PubMed ID: 26310719
[TBL] [Abstract][Full Text] [Related]
6. Emerging treatment for advanced lung cancer with EGFR mutation.
Inal C; Yilmaz E; Piperdi B; Perez-Soler R; Cheng H
Expert Opin Emerg Drugs; 2015; 20(4):597-612. PubMed ID: 26153235
[TBL] [Abstract][Full Text] [Related]
7. Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.
Nurwidya F; Takahashi F; Murakami A; Kobayashi I; Kato M; Shukuya T; Tajima K; Shimada N; Takahashi K
Respir Investig; 2014 Mar; 52(2):82-91. PubMed ID: 24636263
[TBL] [Abstract][Full Text] [Related]
8. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
9. Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy.
Liao BC; Lin CC; Lee JH; Yang JC
Lung Cancer; 2017 Aug; 110():7-13. PubMed ID: 28676222
[TBL] [Abstract][Full Text] [Related]
10. Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures.
Lee DH
Pharmacol Ther; 2017 Jun; 174():1-21. PubMed ID: 28167215
[TBL] [Abstract][Full Text] [Related]
11. Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance.
Tartarone A; Lerose R
Ther Adv Respir Dis; 2015 Oct; 9(5):242-50. PubMed ID: 26016841
[TBL] [Abstract][Full Text] [Related]
12. Transtinib, a potent tyrosine kinase inhibitor inhibits L858R/T790M mutant NSCLC cell lines and xenografts.
Hu P; Han DX; Ruan RS; Zheng LM; Chou SH; Tzeng CM
Oncotarget; 2016 Jun; 7(24):35741-35752. PubMed ID: 26848869
[TBL] [Abstract][Full Text] [Related]
13. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
[TBL] [Abstract][Full Text] [Related]
14. Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours.
Jänne PA
Lung Cancer; 2008 Jun; 60 Suppl 2():S3-9. PubMed ID: 18513582
[TBL] [Abstract][Full Text] [Related]
15. Epidermal Growth Factor Receptor-Mutant Lung Cancer: New Drugs, New Resistance Mechanisms, and Future Treatment Options.
Piotrowska Z; Sequist LV
Cancer J; 2015; 21(5):371-7. PubMed ID: 26389761
[TBL] [Abstract][Full Text] [Related]
16. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
Zou M; Xia S; Zhuang L; Han N; Chu Q; Chao T; Peng P; Chen Y; Gui Q; Yu S
Int J Oncol; 2013 Jun; 42(6):2094-102. PubMed ID: 23588221
[TBL] [Abstract][Full Text] [Related]
17. Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors.
Sun JM; Ahn MJ; Choi YL; Ahn JS; Park K
Lung Cancer; 2013 Nov; 82(2):294-8. PubMed ID: 24035188
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy.
Kanda S; Horinouchi H; Fujiwara Y; Nokihara H; Yamamoto N; Sekine I; Kunitoh H; Kubota K; Tamura T; Ohe Y
Lung Cancer; 2015 Sep; 89(3):287-93. PubMed ID: 26169499
[TBL] [Abstract][Full Text] [Related]
19. Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors.
Chen Q; Quan Q; Ding L; Hong X; Zhou N; Liang Y; Wu H
Oncotarget; 2015 Sep; 6(28):24904-11. PubMed ID: 26172562
[TBL] [Abstract][Full Text] [Related]
20. Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors.
Wong KK
Lung Cancer; 2008 Jun; 60 Suppl 2():S10-8. PubMed ID: 18513579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
